Xenon Pharmaceuticals (XENE) Aandelenoverzicht
Xenon Pharmaceuticals Inc., een biofarmaceutisch bedrijf gericht op neurowetenschappen, houdt zich bezig met het ontdekken, ontwikkelen en leveren van therapeutica voor de behandeling van patiënten met neurologische en psychiatrische aandoeningen. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
XENE Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xenon Pharmaceuticals Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$58.65 |
| 52 Week Hoogtepunt | US$72.66 |
| 52 Week Laag | US$35.60 |
| Bèta | 0.62 |
| 1 maand verandering | -5.93% |
| 3 maanden verandering | 11.93% |
| 1 Jaar Verandering | 61.97% |
| 3 jaar verandering | 59.12% |
| 5 jaar verandering | 228.39% |
| Verandering sinds IPO | 458.57% |
Recent nieuws en updates
Recent updates
Seeking Alpha • Aug 11
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Summary Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027. Robust $1.2B cash position funds operations into 2029, supporting multiple late-stage programs and pipeline expansion. Read the full article on Seeking Alpha
Narratiefupdate • Aug 09
XENE: Upcoming NDA Filing And Kv7 Data Readouts Will Shape Risk Balance
Analysts lifted their fair value estimate for Xenon Pharmaceuticals to $69 from $63, citing updated models that reflect recent Street research and revised long term assumptions on revenue potential, margins, and future P/E expectations. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights both interest in the epilepsy opportunity and a set of clear caution flags that investors should factor into expectations for execution and valuation risk.
Narratiefupdate • Jul 10
XENE: Epilepsy Trial Progress Will Define Edge Versus Slower Kv7 Rival
Analysts have lifted their fair value estimate for Xenon Pharmaceuticals from about $55.40 to about $80.56, reflecting updated models that incorporate revised assumptions for long term revenue potential, profit margins, and future P/E multiples in light of recent Street research and competitive positioning versus Biohaven. Analyst Commentary Recent Street research around Xenon Pharmaceuticals highlights a mix of optimism on the epilepsy opportunity and caution around execution and competitive risk, particularly in comparison with Biohaven.Narratiefupdate • Jun 26
XENE: Phase 3 Success And Mixed Street Views Will Shape Next Chapter
The updated analyst price target for Xenon Pharmaceuticals has moved from $58.58 to $63.00, as analysts factor in refreshed models and recent Street research that includes higher targets from firms such as JPMorgan and Wells Fargo, alongside a modest trim from Needham. Analyst Commentary Recent Street research on Xenon Pharmaceuticals shows a mixed tone, with some large firms, including JPMorgan, lifting price targets while other bearish analysts trim expectations.Nieuw narratief • Mar 27
Epilepsy And Depression Pipeline Will Define Fair Long Term Outlook
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel based therapies for epilepsy, depression, bipolar disorder and pain. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Mar 09
Late Stage Neuroscience Pipeline Will Transform Ion Channel Franchise Over The Coming Years
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Analyse-artikel • Oct 01
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Apr 18
Xenon- A Later Stage Story
Summary Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications. Despite broader biotech market challenges, Xenon's strong efficacy and safety data position it well, with significant interest from major pharma in neurology and neuropsychiatry. Read the full article on Seeking AlphaSeeking Alpha • Jan 16
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Summary Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time. I also believe its late-stage IP is diversified with ion channel modulators for pain and other neurological conditions. So it’s not overly exposed to Azetukalner. I concede that XENE has a premium valuation, but I think 2025 will provide significant clinical data that could justify a “Buy” rating at these levels. Read the full article on Seeking AlphaSeeking Alpha • Aug 09
Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Summary Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage development for epilepsy and Major Depressive Disorder, showing promising results in reducing seizure frequency. Despite a history of failures and low trading volume, Xenon has a strong cash position and upcoming catalysts in phase 3 trials for their lead asset. Read the full article on Seeking AlphaSeeking Alpha • Feb 08
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Summary Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for neurological disorders. The company has experienced "setbacks" in recent trials, but its primary drug candidate, XEN1101, shows significant potential for treating epilepsy. Xenon has initiated Phase 3 clinical trials for XEN1101 and has received myriad positive ratings from analysts, but the stock may be vulnerable to profit-taking. An analysis around Xenon Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 19
Xenon started at outperform at Raymond James on experimental epilepsy drug
Raymond James has initiated Xenon Pharmaceuticals (NASDAQ:XENE) with an outperform rating citing the blockbuster potential of XEN1101, currently in phase 2 for epilepsy. The firm has a $52 price target (~46% upside based on Tuesday's close). Analyst Danielle Brill is confident that XEN1101 will be successful given its strong phase 2 results. She predicted a greater than $1B peak sales opportunity. Xenon (XENE) plans to initiate two identical phase 3 clinical trials. She noted that the the candidate, which is also under development for major depressive disorder, could further benefit from proof-of-concept data in that indication expected in 2023. Brill added that the company's pipeline also presents growth opportunities with XEN496 in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE), and NBI-921352 for SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). XEN1101 is also under investigation for primary generic clonic tonic seizures (PGTCS). In August, BofA started Xenon (XENE) with a buy rating also citing the blockbuster potential of XEN1101 for epilepsy.Seeking Alpha • Sep 06
Putting Xenon Pharmaceuticals Back In The Spotlight
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "Potential has a shelf life." - Margaret Atwood We last looked in on Xenon Pharmaceuticals (XENE) nearly nine months ago. In the summary of that article, the conclusion was that the company had some promising attributes and was worthy of a small 'watch item' via covered call positions. That turned out to be a profitable trade. Time for another potential round trip? We update the investment thesis on Xenon below. Seeking Alpha Company Overview: Xenon Pharmaceuticals is a clinical-stage biotech company focused on developing therapeutics to treat patients with neurological disorders. The company is based just outside of Vancouver, Canada. The stock trades just under $40.00 a share and sports an approximate market cap just north of $2.4 billion. August Company Presentation The company has several compounds in development as can be seen by the pipeline chart above. August Company Presentation The most important asset in development is a candidate called for the moment XEN1011. This is a next generation Kv7 potassium channel opener with potential applications in treating the focal onset seizures which occurs in epileptics as well as other potential neurological disorders. August Company Presentation A Phase 2b trial produced encouraging results in the fourth quarter of last year. The company then disclosed new, compelling efficacy data from that study 'X-TOLE' in June of this year. A Phase 2 study 'X-TOLE2' should initiate by the end of this year, followed shortly by a Phase 3 trial X-TOLE3. If successful, the company plans to submit a market application around this compound to treat epilepsy. August Company Presentation The compound is also in development for other neurological disorders. The company currently has a Phase 2 'X-NOVA' study underway examining XEN1101 in major depressive disorder or MDD. This trial in parallel with an investigator-led Phase 2 MDD study led by Xenon's collaborators at Mount Sinai. Topline results should be out in 2023. August Company Presentation XEN1101 is also now targeting primary generalized tonic clonic seizures or PGTCS. Management plans to initiate a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in PGTCS. This study should kick soon after initiation of the X-TOLE2 trial. August Company Presentation Another compound 'XEN496' is being developed to treat rare KCNQ2-DEE pediatric epilepsy. A Phase 3 study called EPIK, is ongoing to evaluate the efficacy, safety, and tolerability of XEN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. This trial should complete sometime in 2023. August Company Presentation Finally the company has licensed a selective Nav1.6 sodium channel inhibitor 'XEN901', now known as NBI-921352, to Neurocrine Biosciences (NBIX). That compound is in Phase 2 development for a couple of indications. As the result of this licensing agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties on any eventual commercialization. Analyst Commentary & Balance Sheet: Since second quarter results were posted on August 9th, five analyst firms including Needham and Wedbush have reissued Buy ratings on XENE. Price targets proffered ranged from $46 to $52 a share. On August 29th, Bank of America initiated the shares as a new Buy with a $45 a share price target. Here is the commentary from the bank's analyst at the time of that call.Seeking Alpha • Aug 29
Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Bank of America launched its coverage on clinical-stage biotech Xenon Pharmaceuticals Inc. (NASDAQ:XENE) with a Buy rating on Monday, arguing that the company’s mid-stage epilepsy candidate XEN1101 is poised to become a blockbuster drug. XEN1101 belongs to a class of drugs known as Kv7 potassium channel openers, and the drug is expected to undergo its Phase 3 program in H2 2022, XENE said this month. The analysts led by Jason M. Gerberry point to the blockbuster potential of XEN1101 ahead of important catalysts for its safety data, second confirmatory, and label expansion studies. The ease of use, novel mechanism of action, and strong efficacy differentiate XEN1101 from other anti-seizure medications, the team with a $48 per share target on XENE argued. Wall Street stands firmly behind the prospects of Xenon (XENE) with eleven Buy ratings and no Hold or Sell ratings.Seeking Alpha • Dec 13
Sizing Up Xenon Pharmaceuticals
Today, we look at Xenon Pharmaceuticals, a clinical-stage biotech concern with several products advancing in its pipeline. The stock recently has surged on top of positive mid-stage trial results. The shares have also seen some insider buying lately as well. A full investment analysis follows in the paragraphs below.Rendement voor aandeelhouders
| XENE | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -1.8% | -5.2% | -0.9% |
| 1Y | 62.0% | 37.6% | 14.2% |
Rendement versus industrie: XENE overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 37.6 % opleverde.
Rendement versus markt: XENE overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.2 %.
Prijsvolatiliteit
| XENE volatility | |
|---|---|
| XENE Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: XENE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van XENE is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 364 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., een biofarmaceutisch bedrijf dat zich richt op neurowetenschappen, houdt zich bezig met het ontdekken, ontwikkelen en leveren van therapeutica voor de behandeling van patiënten met neurologische en psychiatrische aandoeningen. Haar productkandidaten omvatten Azetukalner, een nieuwe, krachtige Kv7-kaliumkanaalopener die zich in Fase 3 van de klinische ontwikkeling bevindt voor de behandeling van epilepsie, waaronder focale aanvallen en primaire gegeneraliseerde tonisch-clonische aanvallen, evenals neuropsychiatrische aandoeningen, zoals depressieve stoornis en bipolaire depressie. Daarnaast omvatten de Fase 1 Single Ascending Dose/Multiple Ascending Dose-producten van het bedrijf XEN1701 gericht tegen het natriumkanaal en XEN1120 gericht tegen het Kv7-kaliumkanaal voor de behandeling van pijn.
Xenon Pharmaceuticals Inc. Samenvatting
| XENE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$5.68b |
| Inkomsten(TTM) | -US$409.19m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-13.9x
Koers/WinstverhoudingIs XENE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| XENE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$352.49m |
| Brutowinst | -US$352.48m |
| Overige uitgaven | US$56.71m |
| Inkomsten | -US$409.19m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -4.23 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde XENE op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/13 10:34 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Xenon Pharmaceuticals Inc. wordt gevolgd door 25 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Brian Skorney | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| John Newman | Canaccord Genuity |